No Prescription |
 |
 | ||
|
Celebrex Generic Celecoxib |
|
| ||
No Prescription » Prescription Drugs 4 » Celebrex Generic Celecoxib Celebrex is used to treat joint pain tenderness swelling and stiffness:in osteoarthritis and in rheumatoid arthritis Celebrex is also used to relieve short-term pain in cases such as:menstrual cramps (period pain) following surgery dental pain Buy Celebrex Generic Celecoxib and other Prescription Drugs 4 products online at Medstore. Buy Online at Medstore - Click Here!
About Celebrex Generic Celecoxib: Product Type: Prescription Drugs 4 Celebrex ( Generic Celecoxib ) Celebrex (Generic Celecoxib) Generic Celecoxib 100mg 60 Capsules 200mg 30 Capsules Generic Celecoxib Celebrex
View more Prescription Drugs 4 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
